Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 4 | 2019 | 8 | 1.360 |
Why?
|
| Malpractice | 3 | 2015 | 6 | 1.220 |
Why?
|
| Clinical Competence | 2 | 2015 | 96 | 0.830 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 41 | 0.620 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 24 | 0.600 |
Why?
|
| Prostatic Neoplasms | 4 | 2019 | 36 | 0.490 |
Why?
|
| Prostate | 3 | 2019 | 15 | 0.390 |
Why?
|
| Nephrons | 1 | 2012 | 3 | 0.370 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.320 |
Why?
|
| Prostatectomy | 3 | 2005 | 12 | 0.320 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 1 | 0.280 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 15 | 0.270 |
Why?
|
| Nephrectomy | 2 | 2018 | 17 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 70 | 0.260 |
Why?
|
| Humans | 13 | 2019 | 12240 | 0.240 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 61 | 0.230 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 56 | 0.220 |
Why?
|
| Male | 10 | 2019 | 6815 | 0.210 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 7 | 0.190 |
Why?
|
| Glycoproteins | 1 | 2003 | 30 | 0.190 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 1 | 0.190 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 1 | 0.190 |
Why?
|
| Neurilemmoma | 1 | 2002 | 5 | 0.190 |
Why?
|
| Middle Aged | 8 | 2018 | 4043 | 0.180 |
Why?
|
| United States | 3 | 2015 | 989 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 464 | 0.170 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 20 | 0.150 |
Why?
|
| Ultrasonography | 1 | 2019 | 152 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 59 | 0.130 |
Why?
|
| Aged | 5 | 2018 | 4000 | 0.130 |
Why?
|
| Renal Veins | 1 | 2017 | 2 | 0.130 |
Why?
|
| Surgical Stapling | 1 | 2017 | 2 | 0.130 |
Why?
|
| Renal Artery | 1 | 2017 | 4 | 0.130 |
Why?
|
| Adult | 4 | 2018 | 3557 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2017 | 95 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 247 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2017 | 385 | 0.100 |
Why?
|
| SEER Program | 1 | 2013 | 8 | 0.100 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 15 | 0.100 |
Why?
|
| Young Adult | 2 | 2017 | 863 | 0.100 |
Why?
|
| Melanoma | 1 | 2013 | 34 | 0.100 |
Why?
|
| Kidney | 1 | 2013 | 87 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 152 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2018 | 1467 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 6 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 16 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 13 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 41 | 0.080 |
Why?
|
| Female | 4 | 2018 | 6974 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 99 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 281 | 0.070 |
Why?
|
| Time Factors | 1 | 2010 | 695 | 0.070 |
Why?
|
| Comorbidity | 2 | 2013 | 209 | 0.070 |
Why?
|
| Incidence | 2 | 2018 | 338 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 252 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 3 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 5 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 726 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2003 | 60 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 151 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 86 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 2152 | 0.050 |
Why?
|
| Education | 1 | 2019 | 16 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 15 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 23 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 118 | 0.030 |
Why?
|
| Lung | 1 | 2018 | 76 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 168 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 116 | 0.030 |
Why?
|
| Ligation | 1 | 2017 | 19 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 8 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 38 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 115 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 141 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 161 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2017 | 1478 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 295 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 4 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 8 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 10 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 97 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 1049 | 0.020 |
Why?
|